The evolving relationship between Chlamydia pneumoniae and atherosclerosis

Current Opinion in Infectious Diseases

Volumn 13, Issue 6, 2000, Pages 583-591

  Dunne, Michael ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; GATIFLOXACIN; IMMUNOGLOBULIN G; ROXITHROMYCIN; VIRUS ANTIBODY;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HEART DISEASE; HUMAN; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; RESTENOSIS; REVIEW; RISK FACTOR; SCREENING; SEROEPIDEMIOLOGY;

EID: 0033668181     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200012000-00002     Document Type: Review

References (74)

1. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
2. Chlamydia pneumoniae and atherosclerosis
3. Chlamydia pneumoniae and atherosclerosis
4. The association of Chlamydia pneumoniae and atherogenesis
5. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: Meta-analyses of prospective studies
6. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease
7. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
8. Chlamydia, H pylori and cytomegalovirus seropositivity and risk of cardiovascular disease: The Framingham Heart Study
9. Chlamydia pneumoniae infection and incident coronary heart disease: The atherosclerosis risk in communities study
10. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction
11. Infections, inflammation, and the risk of coronary heart disease
12. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study
13. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: Large prospective study
14. Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in a sample population from Italy
15. Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: Negative results of a case-control study
16. Chlamydia pneumoniae in the ischemic heart disease
17. No serological evidence of association between Chlamydia pneumoniae infection and acute coronary heart disease
18. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not
19. Chlamydia pneumoniae antibody titres are significantly associated with acute stroke and transient cerebral ischemia: The West Birmingham Stroke Project
20. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension
21. Chlamydia pneumoniae and the risk of first ischemic stroke
22. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions: Results from a nested case-control study in northern Sweden
23. The progression of lower limb atherosclerosis is associated with IgA antibodies against Chlamydia pneumoniae
24. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis
25. Commentary: Adjustment for potential confounders may have been taken too far
26. Atherosclerosis: An inflammatory disease
27. Risk factors for coronary heart disease and persistent infection with Chlamydia pneumoniae or cytomegalovirus: A population-based study
28. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients
29. Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease
30. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease
31. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease
32. Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease
33. Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation
34. Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction
35. The prevalence of Chlamydia pneumoniae in atherosclerotic and non atherosclerot c blood vessels of patients attending for redo and first time coronary artery bypass graft surgery
36. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection?
37. Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery
38. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and historical severity (Stary Grading) of associated atherosclerotic plaque
39. Monocyte-endothelial cell coculture enhances infection of endothelial cells with Chlamydia pneumoniae
40. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes
41. Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation
42. Construction of an internal control for the detection of Chlamydia pneumoniae by PCR
43. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis
44. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
45. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors
46. The prevalence of chronic Chlamydia pneumoniae infection as detected by polymerase chain reaction in pharyngeal samples from patients with ischemic heart disease
47. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease
48. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection
49. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction
50. Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of humans and koalas
51. Monocyte-endothelial cell coculture enhances infection of endothelial cells with Chlamydia pneumoniae
52. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes
53. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF·κband induces tissue factor and PAI-1 expression: A potencial link to accelarated arteriosclerosis
54. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells
55. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s)
56. Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms
57. Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery
58. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide
59. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae
60. Rabbit model for Chlamydia pneumoniae infection
61. Animal models for Chlamydia pneumoniae infection
62. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice
63. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae
64. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model?
65. Chlamydia pneumoniae, antimicrobial therapy and coronary heart disease: A critical overview
66. Chlamydia pneumoniae: Inflammation and instability of the atheroscerotic plaque
67. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The azithromycin in coronary artery disease: Elimination of myocardial infection with chlamydia (ACADEMIC) Study
68. Roxithromycin for prevention of restenosis after stenting; results of the randomized, double blind placebo controlled intracoronary stenting and antibiotic regimen trials (ISAR)
69. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline
70. Detection of microorganisms in vessel wall specimens of the abdominal aorta: Development of a PCR assay in the absence of a gold standard
71. Safety and effect on anti-Chlamydia pneumoniae antibody titers of a 1 month course of daily azithromycin in adults with coronary artery disease
72. Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomized treatment study